Market Place
Sourcing Support
FDA oncology to weigh Exelixis` Cabometyx in neuroendocrine tumors
30 Nov 2024 //
FIERCE PHARMA
Exelixis Provides Update on Cabozantinib for Neuroendocrine Tumors
26 Nov 2024 //
BUSINESSWIRE
Exelixis stock rises as Cabometyx withstands patent challenge
16 Oct 2024 //
FIERCE PHARMA
Exelixis presses on with FDA prostate cancer bid as Ipsen scraps EU plan
17 Sep 2024 //
FIERCE PHARMA
Exelixis Presents CABINET Study Results At ESMO 2024
16 Sep 2024 //
BUSINESSWIRE
Cabometyx Efficacy In Neuroendocrine Tumors Reinforced
16 Sep 2024 //
GLOBENEWSWIRE
Exelixis Presents CONTACT-02 Results For Cabozantinib Combo At ESMO
15 Sep 2024 //
BUSINESSWIRE
Ipsen Updates On CONTACT-02 Trial In Prostate Cancer After Final Analysis
15 Sep 2024 //
GLOBENEWSWIRE
Arcus Biosciences Reports Q2 2024 Results And Pipeline Update
08 Aug 2024 //
BUSINESSWIRE
FDA Accepts Exelixis` sNDA For Cabozantinib In Advanced NET
06 Aug 2024 //
BUSINESSWIRE
Exelixis Announces Second Quarter 2024 Financial Results and Corporate Update
06 Aug 2024 //
BUSINESSWIRE
Verastem Announces Proposed Public Offering Of Stock And Warrants
23 Jul 2024 //
BUSINESSWIRE
Ipsen Expands Cabometyx Collaboration For Neuroendocrine Tumors
02 Jul 2024 //
GLOBENEWSWIRE
Exelixis Settles CABOMETYX Patent Litigation With Cipla
20 May 2024 //
BUSINESSWIRE
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib
06 Mar 2024 //
GLOBENEWSWIRE
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
26 Jan 2024 //
ENDPTS
Latest PIII trial data investigating Cabometyx to be presented at ASCO GU 2024
22 Jan 2024 //
GLOBENEWSWIRE
European Patent Office Rules in Favor of Exelixis on Formulation Patent
18 Jan 2024 //
BUSINESSWIRE
Results from Phase 3 Evaluating Cabozantinib in Neuroendocrine Tumors Presented
22 Oct 2023 //
PRESS RELEASE
Exelixis ends Cabometyx study after seeing dramatic improvements
25 Aug 2023 //
FIERCE PHARMA
Exelixis, Teva reach settlement on Cabometyx patent dispute
25 Jul 2023 //
ENDPTS
Roche, Exelixis` Tecentirq-Cabometyx fails a 3rd time
04 Mar 2023 //
FIERCE PHARMA
Exelixis Provides Update on PIII Trial Evaluating Cabozantinib with Atezolizumab
02 Mar 2023 //
BUSINESSWIRE
Opdivo in Combination with CABOMETYX Shows Durable Survival
13 Feb 2023 //
BUSINESSWIRE
Aravive to Present Positive Data from P1b Trial of Batiraxcept with Cabozantinib
13 Feb 2023 //
GLOBENEWSWIRE
Exelixis/Roche Combo Fails to Improve Overall Survival in NSCLC
10 Dec 2022 //
BIOSPACE
Ipsen Provides Update On PIII Trial Evaluating Cabozantinib With Atezolizumab
08 Dec 2022 //
BUSINESSWIRE
Exelixis Announces Dose-Escalation Results from the PI STELLAR-001 Trial
10 Sep 2022 //
BUSINESSWIRE
Exelixis Announces Results from PIII COSMIC-313 Pivotal Trial in Patients
07 Sep 2022 //
BUSINESSWIRE
Exelixis Seeks to Block Generic Version of Kidney Cancer Drug
02 Sep 2022 //
FIRSTWORLDPHARMA
Exelixis Announces Second Quarter 2022 Financial Results
09 Aug 2022 //
BUSINESSWIRE
EC Approves Cabometyx as 2L Treatment in Radioactive Iodine-Refractory DTC
03 May 2022 //
BUSINESSWIRE
Ipsen Receives EC Approval for CABOMETYX for Thyroid Cancer
03 May 2022 //
BUSINESSWIRE
Ipsen Receives Positive CHMP Opinion for CABOMETYX in Thyroid Cancer
25 Mar 2022 //
BUSINESSWIRE
Exelixis axes Cabometyx-Tecentriq combo in liver cancer
16 Mar 2022 //
FIERCEPHARMA
Exelixis` Final OS Results from Phase 3 COSMIC-31 Trial of Cabozantinib in Combo
14 Mar 2022 //
BUSINESSWIRE
Ipsen: Cabometyx in Combination With Opdivo Demonstrated Continued Survival
15 Feb 2022 //
BUSINESSWIRE
Opdivo with CABOMETYX Demonstrates Continued Survival Benefits in RCC
14 Feb 2022 //
BUSINESSWIRE
Exelixis Shows Results for Cabozantinib in Colorectal Cancer at ASCO GI 2022
18 Jan 2022 //
BUSINESSWIRE
Exelixis Completes Enrollment in Phase 3 Trial of Cabozantinib+Atezolizumab
05 Jan 2022 //
BUSINESSWIRE
Exelixis: Phase 3 Results Trial of Cabozantinib + Immune Checkpoint Inhibitor
20 Nov 2021 //
BUSINESSWIRE
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Cabozantinib
09 Nov 2021 //
PRESS RELEASE
SMC accepts Cabometyx/Opdivo combo for advanced kidney cancer patients
13 Oct 2021 //
PHARMATIMES
Ipsen poaches Novartis vet Mari Scheiffele
11 Oct 2021 //
FIERCEPHARMA
FDA approves Exelixis’ Cabometyx for differentiated thyroid cancer
21 Sep 2021 //
PHARMATIMES
Exelixis Announces PIb Results from COSMIC-021 Trial in Metastatic CRPC
18 Sep 2021 //
BUSINESSWIRE
Exelixis touts early prostate cancer data for Cabometyx combo
17 Sep 2021 //
FIERCEPHARMA
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib)
17 Sep 2021 //
BUSINESSWIRE
Ipsen:ESMO 2021:Cabometyx® Demonstrates Sustained 78% Reduction Risk of Disease
17 Sep 2021 //
BUSINESSWIRE
Exelixis: CABOMETYX in Combination with OPDIVO Provides Efficacy Benefits
16 Sep 2021 //
BUSINESSWIRE
BDR Pharma launches cabozantinib to treat metastatic medullary thyroid cancer
14 Sep 2021 //
PHARMABIZ
Exelixis partner Takeda & Ono bag Japanese approval for Cabometyx +Opdivo in RCC
27 Aug 2021 //
PHARMABIZ
Takeda and Ono Receive Approval for CABOMETYX® in Combination with OPDIVO®
25 Aug 2021 //
BUSINESSWIRE
Exelixis & Ipsen`s Cabozantinib, Checkpoint Inhibitor combo Ups Survival
28 Jun 2021 //
BUSINESSWIRE
Exelixis & Ipsen Announced Results from Phase 3 COSMIC-311 Pivotal Trial
07 Jun 2021 //
BUSINESSWIRE
Final Data from Calithera Biosciences’ Ph2 CANTATA Study Presented at 2021 ASCO
07 Jun 2021 //
GLOBENEWSWIRE
Ipsen opts-in to join Exelixis with ongoing development of Cabometyx®
11 May 2021 //
IPSEN
EC Approves BMS’ Opdivo in Combination with Cabometyx for Advanced RCC
16 Apr 2021 //
PHARMTECH
GSK offloads royalty rights for 2 cancer drugs in $342M windfall it will use
02 Apr 2021 //
ENDPTS
